Synendos Therapeutics is a biopharmaceutical company focused on developing groundbreaking and effective therapies for neuropsychiatric disorders. They achieve this by targeting the endocannabinoid system, a key neuromodulator system in the brain. By modulating a newly identified drug target responsible for endocannabinoid cell reuptake, Synendos aims to restore the natural functioning of the brain.

Their lead drug candidate, SYT-510, is a novel Selective Endocannabinoid Re-uptake Inhibitor (SERI) that represents a first-in-class, self-limiting modulator of the endocannabinoid system. This innovative approach has the potential to offer significant benefits to patients suffering from anxiety and mood-related disorders like post-traumatic stress disorder (PTSD). Synendos is a spin-out from the University of Bern and benefits from the extensive expertise of Prof Jürg Gertsch and the ECS research group.

They have secured a Series A funding round of CHF 24m and have additional grant funding, showcasing the validation of their technology and the potential success of their work. With a focus on providing safer and more effective therapies for CNS disorders, Synendos is poised to enter clinical studies with SYT-510 in 2023, marking a transition to a clinical stage biotech company. Their assets and targets are protected by robust patents, ensuring the exclusivity of their innovative approach.

For more information, Synendos encourages contacting them directly through their email or social media channels